Outcomes of thalassemia patients undergoing hematopoietic stem cell transplantation by using a standard myeloablative versus a novel reduced-toxicity conditioning regimen according to a new risk stratification.

导出 OA

翻译打印收藏纠错

作者： Usanarat,Anurathapan ^[1] ; Samart,Pakakasama ^[1] ; Pimsiri,Mekjaruskul ^[1] ; Nongnuch,Sirachainan ^[1] ; Duantida,Songdej ^[1] ; Ampaiwan,Chuansumrit ^[1] ; Pimlak,Charoenkwan ^[2] ; Arunee,Jetsrisuparb ^[3] ; Kleebsabai,Sanpakit ^[4] ; Bunchoo,Pongtanakul ^[4] ; Piya,Rujkijyanont ^[5] ; Arunotai,Meekaewkunchorn ^[6] ; Rosarin,Sruamsiri ^[7] ; Artit,Ungkanont ^[8] ; Surapol,Issaragrisil ^[9] ; Borje S,Andersson ^[10] ; Suradej,Hongeng ^[11]

作者单位： Department of Pediatrics, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. ^[1] Department of Pediatrics, Chiangmai University Hospital, Chiangmai, Thailand. ^[2] Department of Pediatrics, Khonkaen University, Khonkaen, Thailand. ^[3] Department of Pediatrics, Siriraj Hospital, Mahidol University, Bangkok, Thailand. ^[4] Department of Pediatrics, Phramongkutklao Hospital, Bangkok, Thailand. ^[5] Queen Sirikit National Institute of Child Health, Bangkok, Thailand. ^[6] Center of Pharmaceutical Outcomes Research, Department of Pharmacy Practice, Naresuan University, Phitsanulok, Thailand. ^[7] Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. ^[8] Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand. ^[9] Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas. ^[10] Department of Pediatrics, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. Electronic address: suradej.hon@mahidol.ac.th. ^[11]

关键词 Myeloablative Reduced toxicity Thalassemia